Valneva announces sale of priority review voucher for $103 million

Saint-herblain (france), february 5, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced it sold the priority review voucher (prv) it received from the u.s. food and drug administration (fda) for $103 million (€95 million).

VALN Ratings Summary

VALN Quant Ranking